A phase II evaluation of pemetrexed (Alimta, LY231514, IND #40061) in the treatment of recurrent or persistent endometrial carcinoma: A phase II study of the Gynecologic Oncology

David Scott Miller, John A. Blessing, Richard D. Drake, Robert Higgins, D. Scott McMeekin, Louis V. Puneky, Carolyn N. Krasner

Research output: Contribution to journalArticle

27 Scopus citations


Objective: To estimate the anti-tumor activity of pemetrexed in patients with advanced or recurrent carcinoma of the endometrium and to determine the nature and degree of toxicity. Methods: A multicenter phase II trial was conducted by the Gynecologic Oncology Group (GOG). Patients must have had advanced or recurrent measurable carcinoma of the endometrium and failed one prior chemotherapy regimen. Pemetrexed at a dose of 900 mg/m2 was administered as an IV infusion over 10 min every 21 days. Results: From May 1, 2006 to July 31, 2007, 27 patients were entered by 10 member institutions of the GOG with two patients being deemed ineligible. A total of 101 cycles were administered with 28% of patients receiving five or more cycles. Overall, the treatment was well tolerated. More serious toxicities (grade 3 and 4) included anemia in 20%, leukopenia in 40%, neutropenia in 48%, and constitutional in 16%. No treatment-related deaths were reported. One patient (4%) had a partial response. Eleven patients (44%) had stable disease and eleven (44%) patients had increasing disease. Response could not be assessed in two patients (7%). Median progression-free survival was 2.7 months and overall survival was 9.4 months. Conclusion: Pemetrexed has minimal activity in the treatment of recurrent or persistent endometrial carcinoma at the dose and schedule tested.

Original languageEnglish (US)
Pages (from-to)443-446
Number of pages4
JournalGynecologic Oncology
Issue number3
Publication statusPublished - Dec 2009



  • Alimta, GOG
  • Cancer of the endometrium
  • Pemetrexed

ASJC Scopus subject areas

  • Obstetrics and Gynecology
  • Oncology

Cite this